ClinicalTrials.gg
Not yet recruitingNCT07561996MovámonosUpdated Nov 9, 2026

A 12-week Field Trial of the Movámonos Physical Activity Support Program

An interventional study of Movámonos Physical Activity Support Program in Overweight and Obese Adults and Physical Inactivity, sponsored by University of Colorado, Denver. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

Updated Nov 9, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Overweight by University of Colorado, Denver — 3 open to participants now, 12 under way, none of them phase 3. Overweight · University of Colorado, Denver.

Planned enrollment
22nd of 29
20 · median 36
Started
2027
the only one that year
No phase
29 of 30
3 open now
Primary completion
2027-07
later than 8 of 11 live
Registered
30th of 30
by date

Among the 30 studies in Overweight by University of Colorado, Denver, this one is the 22nd largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2027, is one of 29 with no phase, reaches primary completion later than 8 of the 11 other live ones, and was the 30th registered.

Overweight

3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.

Browse Overweight studies →

Open to participants now

3 of the 30 studies in Overweight by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Overweight by University of Colorado, Denver, or all of them as a file.
02

Study summary

The objective of this study is to design and refine an activity support program, called Movámonos, for adults with overweight or obesity who speak Spanish. The primary outcomes are feasibility and acceptability of the Movámonos physical activity support program.

Read the detailed description

The purpose of this study is to pilot test a 12-week physical activity support program, called Movámonos, designed for Spanish-speaking adults with overweight or obesity. Movámonos includes four intervention components: 1) weekly 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) group fitness classes, and 4) mental guided imagery sessions. Participants will be asked to build their physical activity levels up to 150 minutes/week. The primary outcome is to evaluate the program's acceptability and feasibility from the participant perspective.

03

Conditions studied

  • Overweight and Obese Adults
  • Physical Inactivity

Keywords

  • physical activity
  • lifestyle intervention
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and Women
  • Age 18-65 years
  • Speak Spanish as their primary language
  • Self-identify as Hispanic or Latino
  • 25-45 kg/m2
  • Insufficiently active (defined as \<150 min/week of voluntary exercise at moderate intensity over the past 3 months)
  • Willing not to enroll in any other formal weight loss, physical activity program, or fitness center membership over the next 6 months.
  • Capable and willing to give , understand exclusion criteria, attend the Movámonos program sessions, and complete outcome measures.
  • Able to provide signed physician clearance for exercise if indicated by the Physical Activity Readiness Questionnaire (PAR-Q+) and determined by the study Principle Investigator (PI).

Exclusion criteria

Exclusion Criteria:

  • Considered high risk, based on the American College of Sports Medicine Guidelines for Exercise Testing and Prescription (i.e. have cardiovascular disease symptoms or known cardiovascular disease, diabetes, or end-stage renal disease). These conditions are identified in the Physical Activity Readiness Questionnaire (PAR-Q+) .
  • Females who are currently pregnant or lactating, were pregnant within the past 3 months, or planning to become pregnant in the next 6 months will also be excluded
  • Self-reported cardiovascular disease:
  • Cardiac, peripheral vascular, or cerebrovascular disease
  • Self-reported symptoms suggestive of cardiovascular disease: pain, discomfort in the chest, neck, jaw, arms, or other areas that may result from cardiac ischemia; shortness of breath at rest or with mild exertion; dizziness or syncope; orthopnea or paroxysmal nocturnal dyspnea; ankle edema; palpitations or tachycardia; intermittent claudication.
  • Self-reported end-stage renal disease
  • Self-reported diabetes (history of type 1 or type 2 diabetes; fasting glucose ≥126 mg/dL or ≥6.5%)
  • Uncontrolled hypertension, defined as diastolic blood pressure >100 mmHG, systolic blood pressure >160 mmHG, or resting heart rate >100 bpm as measured in duplicate at the screening visit after 5 minutes of rest in a seated position.
  • Self-reported pulmonary disease requiring chronic oxygen supplementation; severe asthma or requiring hospitalization in past year.
  • Plans to relocate in the next 6 months
  • Currently participating in or planning to participate in any formal weight loss, dietary modification, or physical activity/exercise programs or clinical trials.
  • Current severe depression or history of severe depression within the previous year, based on criteria for Major Depressive Episode. Scores >=16 on the Center for Epidemiologic Studies Depression Scale (CES-D) will require further assessment by the Study PI to determine if it is appropriate for the subject to participate in the study.
  • History of other significant psychiatric illness (e.g., psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study PI would interfere with ability to adhere to the exercise intervention.
  • History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Scores >20 on the Eating Attitudes Test (EATS-26 Spanish version) or global scores ≥2.3 on the Spanish version of the Eating Disorder Examination Questionnaire (S-EDE-Q) suggestive of a possible eating disorder will require further assessment by the Study PI to determine if it is appropriate for the subject to participate in the study.
  • Current alcohol or substance abuse
  • Nicotine use (current or past 6 months)
  • Regular use of prescription or over-the-counter medications known to significantly impact appetite, weight, sleep, or energy metabolism (e.g., appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants)
  • Regular use of obesity pharmacotherapeutic agents within the last 6 months.
  • Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed > 1 year before screening, (2) lap banding if the band has been removed > 1 year before screening, (3) intragastric balloon if the balloon has been removed > 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed > 1 year before screening.
  • Undiagnosed hypo- or hyper-thyroidism (thyroid stimulating hormone (TSH) outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.
  • Hematocrit, white blood cell count or significantly outside the normal reference range.
  • Triglycerides > 400 mg/dL
  • low density lipoprotein (LDL) cholesterol >200 mg/dL
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Movámonos physical activity support program

    Participants receive the physical activity support program over 12 weeks.

    Behavioral: Movámonos Physical Activity Support Program

Interventions

  • BehavioralMovámonos Physical Activity Support Program

    The 12-week Movámonos program includes four intervention components: 1) weekly, 60-minute group-based classes, 2) 3, 45-minute individualized support sessions, 3) group fitness classes, and 4) weekly mental guided imagery sessions. Participants will be asked to build up their physical activity levels up to 150 minutes/week.

06

What researchers measure

Primary outcomes

  1. Program Acceptability - Qualitative

    Acceptability of the physical activity support program will be assessed with results of the semi-structured focus groups or interviews from the participant perspective.

    Time frame: 3 months

  2. Program Feasibility - Qualitative

    Feasibility of the physical activity support program will be assessed with results of the semi-structured focus groups or interviews from the participant perspective.

    Time frame: 3 months

Secondary outcomes

  1. Program Acceptability - Quantitative

    Acceptability of the physical activity support program components will be assessed using the Acceptability of Intervention Measure (AIM) from the participant perspective. Scores range from 0 to 5, with higher scores indicating a better outcome.

    Time frame: 3 months

  2. Program Feasibility - Quantitative

    Feasibility of the physical activity support program will be assessed using the Feasibility of Intervention Measure (FIM). Scores range from 0 to 5, with higher scores indicating a better outcome.

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Participants have not consented to individual level data being shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2027, 6 months later.

Of 1,314 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 6 months is below that.

Counting every sponsor, half of 1,427 studies reached it within 17 months; a quarter within 7 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start May 2026 → Jan 2027, primary completion Dec 2026 → Jul 2027 and completion Jul 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 1, 2026
StartEst.
Jan 30, 2027was May 2026
Primary completionEst.
Jul 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Jul 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 15, 2026→Jan 30, 2027
Nov 9, 2026
Primary completion
Dec 31, 2026→Jul 31, 2027
Nov 9, 2026
Study completion
Jul 31, 2027→Dec 31, 2027
Nov 9, 2026
Eligibility
1 inclusion criterion edited; 5 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAble to provide signed physician clearance for exercise if indicated by the Physical Activity Readiness Questionnaire (PAR-Q+) and determined by the study Principle Investigator (PI).
Exclusion criteria
  • EditedConsidered high risk, based on the American College of Sports Medicine Guidelines for Exercise Testing and Prescription33Prescription (i.e. have cardiovascular disease symptoms or known cardiovascular disease, diabetes, or end-stage renal disease). These conditions are identified in the Physical Activity Readiness Questionnaire (PAR-Q+) .
  • EditedCurrent severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. Scores >=16 on the Center for Epidemiologic Studies Depression Scale (CES-D) will require further assessment by the Study PI to determine if it is appropriate for the subject to participate in the study.
  • EditedHistory of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Scores >20 on the Eating Attitudes Test (EATS-26 Spanish version34version) or global scores ≥2.3 on the Spanish version of the Eating Disorder Examination Questionnaire (S-EDE-Q)35,36 suggestive of a possible eating disorder will require further assessment by the Study PI to determine if it is appropriate for the subject to participate in the study.
  • EditedUndiagnosed hypo- or hyper-thyroidism (thyroid stimulating hormone (TSH) outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.
  • Editedlow density lipoprotein (LDL) cholesterol >200 mg/dL
Nov 9, 2026
Contact
Study contact changed: r•••@cuanschutz.edu · •••0819→v•••@cuanschutz.edu · •••9052. See the current contact
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date May 15, 2026→Jan 30, 2027
    Primary completion Dec 31, 2026→Jul 31, 2027
    Study completion Jul 31, 2027→Dec 31, 2027
    Eligibility 1 inclusion criterion edited; 5 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAble to provide signed physician clearance for exercise if indicated by the Physical Activity Readiness Questionnaire (PAR-Q+) and determined by the study Principle Investigator (PI).
    Exclusion criteria
    • EditedConsidered high risk, based on the American College of Sports Medicine Guidelines for Exercise Testing and Prescription33Prescription (i.e. have cardiovascular disease symptoms or known cardiovascular disease, diabetes, or end-stage renal disease). These conditions are identified in the Physical Activity Readiness Questionnaire (PAR-Q+) .
    • EditedCurrent severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. Scores >=16 on the Center for Epidemiologic Studies Depression Scale (CES-D) will require further assessment by the Study PI to determine if it is appropriate for the subject to participate in the study.
    • EditedHistory of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Scores >20 on the Eating Attitudes Test (EATS-26 Spanish version34version) or global scores ≥2.3 on the Spanish version of the Eating Disorder Examination Questionnaire (S-EDE-Q)35,36 suggestive of a possible eating disorder will require further assessment by the Study PI to determine if it is appropriate for the subject to participate in the study.
    • EditedUndiagnosed hypo- or hyper-thyroidism (thyroid stimulating hormone (TSH) outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.
    • Editedlow density lipoprotein (LDL) cholesterol >200 mg/dL
    Contact Study contact changed: r•••@cuanschutz.edu · •••0819→v•••@cuanschutz.edu · •••9052. See the current contact
    + 4 other changes: index terms, verification date, responsible party and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07561996
Collaborators
The University of Tennessee, Knoxville
Responsible party
Sponsor
First posted
May 1, 2026
Start date
Jan 30, 2027 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Danielle Ostendorf, PhD
Contact
dostendo@utk.edu
18659748606
Victoria Catenacci, MD
Contact
vicki.catenacci@cuanschutz.edu
1303-724-9052

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion